TNXP - Tonix Pharmaceuticals Holding Corp.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Tonix Pharmaceuticals Holding Corp.

509 Madison Avenue
Suite 306
New York, NY 10022
United States

IndustryDrug Manufacturers - Major
Full Time Employees18

Key Executives

Dr. Seth Lederman M.D.Co-Founder, Pres, CEO & Chairman472.5kN/A60
Mr. Bradley Saenger CPACFO & Treasurer301.36kN/A44
Dr. Gregory M. Sullivan M.D.Chief Medical Officer & Sec.335kN/A52
Mrs. Jessica Edgar MorrisExec. VP of OperationsN/AN/AN/A
Dr. Ronald R. Notvest Ph.D., MBAExec. VP of Commercial Planning and Devel.N/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Tonix Pharmaceuticals Holding Corp. engages in developing pharmaceutical and biological products to address public health challenges. Its lead product candidate, TNX-102 SL or Tonmya, designed as a bedtime treatment for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population. The company is also developing TNX-601 (tianeptine oxalate), a clinical candidate at pre-IND (investigational new drug) application stage, designed as a daytime treatment for posttraumatic stress disorder (PTSD); and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.

Corporate Governance

Tonix Pharmaceuticals Holding Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.